537 related articles for article (PubMed ID: 16503832)
1. Emerging drugs for chemotherapy-induced emesis.
Navari RM; Province PS
Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
3. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Navari RM
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2738-46. PubMed ID: 25838122
[TBL] [Abstract][Full Text] [Related]
4. Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
Navari RM
Expert Opin Pharmacother; 2009 Mar; 10(4):629-44. PubMed ID: 19284365
[TBL] [Abstract][Full Text] [Related]
5. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Navari RM
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Navari RM
Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
Celio L; Agustoni F; Testa I; Dotti K; de Braud F
Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
[TBL] [Abstract][Full Text] [Related]
8. New antiemetic drugs.
Roila F; Fatigoni S
Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997
[TBL] [Abstract][Full Text] [Related]
9. Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
Navari RM
J Natl Compr Canc Netw; 2007 Jan; 5(1):51-9. PubMed ID: 17239326
[TBL] [Abstract][Full Text] [Related]
10. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
Celio L; Denaro A; Canova S; Gevorgyan A; Bajetta E
Tumori; 2008; 94(4):447-52. PubMed ID: 18822676
[TBL] [Abstract][Full Text] [Related]
11. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Pharmacother; 2014 Dec; 15(17):2599-608. PubMed ID: 25323946
[TBL] [Abstract][Full Text] [Related]
12. The current status of the use of palonosetron.
Navari R
Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Wang SY; Yang ZJ; Zhang L
Asian Pac J Cancer Prev; 2014; 15(22):9587-92. PubMed ID: 25520071
[TBL] [Abstract][Full Text] [Related]
14. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
15. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.
Navari RM
Drugs; 2009; 69(5):515-33. PubMed ID: 19368415
[TBL] [Abstract][Full Text] [Related]
17. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
[TBL] [Abstract][Full Text] [Related]
18. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
20. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Shirley M
Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]